These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38297192)

  • 1. Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    Verghote F; Van Praet C; Berquin C; Lumen N; Decaestecker K; Vanneste B; Rammant E; Fonteyne V
    BMC Cancer; 2024 Jan; 24(1):160. PubMed ID: 38297192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder preservation in urothelial carcinoma: current trends and future directions.
    Goodstein T; Wang SJ; Lee CT
    Curr Opin Support Palliat Care; 2021 Dec; 15(4):253-259. PubMed ID: 34726191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer].
    Fleischmann M; Rödel C
    Strahlenther Onkol; 2023 Sep; 199(9):871-873. PubMed ID: 37532957
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Cigliola A; Mercinelli C; Patanè D; Raggi D; Necchi A
    Eur Urol; 2023 Dec; 84(6):602-603. PubMed ID: 37451897
    [No Abstract]   [Full Text] [Related]  

  • 6. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Konieczkowski DJ; Efstathiou JA; Mouw KW
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The first experience in Hungary with split-course multimodal treatment in high risk bladder cancer].
    Fazekas F; Bíró K; Ágoston P; Nagyiványi K; Gonda G; Buzogány I; Beöthe T
    Orv Hetil; 2021 Dec; 162(50):2017-2022. PubMed ID: 34896984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patients' Perspectives.
    Rammant E; Fonteyne V; Van Goethem V; Verhaeghe S; Raes A; Van Hemelrijck M; Mohamed NE; Decaestecker K; Van Hecke A
    Semin Oncol Nurs; 2021 Dec; 37(6):151226. PubMed ID: 34758914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
    Koga F; Kihara K
    Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices.
    Mohamed NE; Pisipati S; Lee CT; Goltz HH; Latini DM; Gilbert FS; Wittmann D; Knauer CJ; Mehrazin R; Sfakianos JP; McWilliams GW; Quale DZ; Hall SJ
    Urol Oncol; 2016 Dec; 34(12):531.e7-531.e14. PubMed ID: 27449687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Johnson SB; Yu JB
    Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Seisen T; Rouprêt M; Blanchard P
    Eur Urol; 2024 Jan; 85(1):e24. PubMed ID: 37659960
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer.
    Ballas L; Singh P; Lerner SP
    Urol Oncol; 2023 Jan; 41(1):35-38. PubMed ID: 33153882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of quality of life in muscle-invasive bladder cancer survivors.
    Tsai YS; Wu TY; Ou CH; Cheng HL; Tzai TS; Yang WH; Wang JD
    BMC Urol; 2022 Aug; 22(1):126. PubMed ID: 35987634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed.
    Jena R; Issa R; Perry M
    Lancet Oncol; 2023 Aug; 24(8):e324. PubMed ID: 37541275
    [No Abstract]   [Full Text] [Related]  

  • 20. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    Gore JL; Wolff EM; Comstock BA; Follmer KM; Nash MG; Basu A; Chisolm S; MacLean DB; Lee JR; Lotan Y; Porten SP; Steinberg GD; Chang SS; Gilbert SM; Kessler LG; Smith AB;
    BMC Cancer; 2023 Nov; 23(1):1127. PubMed ID: 37980511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.